Possible role of minor H antigens in the persistence of donor chimerism after stem cell transplantation; Relevance for sustained leukemia remission

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Van Der Torren, Cornelis R ^a   Van Hensbergen, Yvette ^b   Luther, Susanne ^c   Aghai, Zohara ^a   Rychnavská, Zuzana Stachová ^a   Slot, Manon ^b   Scherjon, Sicco ^a   Kröger, Nicolaus ^d   Ganser, Arnold ^c   Weissinger, Eva M ^c   Goulmy, Els ^a   Hambach, Lothar ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; HA 1 ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; UNCLASSIFIED DRUG; CD133 ANTIGEN; GLYCOPROTEIN; HA-1 ANTIGEN; LEUKOCYTE ANTIGEN; OLIGOPEPTIDE; PEPTIDE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN FUNCTION; ARTICLE; CELL ISOLATION; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HEMATOPOIESIS; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOCYTE FUNCTION; MALE; MIDDLE AGED; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; STEM CELL TRANSPLANTATION; YOUNG ADULT; ALLOTRANSPLANTATION; GENETICS; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGY; LEUKEMIA; METABOLISM;

MUS;

AC133 ANTIGEN; ANTIGENS, CD; ANTIGENS, CD34; GLYCOPROTEINS; GRAFT VS LEUKEMIA EFFECT; HUMANS; LEUKEMIA; MINOR HISTOCOMPATIBILITY ANTIGENS; OLIGOPEPTIDES; PEPTIDES; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 84924973706     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119595     Document Type: Article

References (50)

1. Horowitz M, Gale R, Sondel P, Goldman J, Kersey J, Kolb H, et al. Graft-verus-leukemia reactions after bone-marrow transplantation. Blood. 1990;75:555-562. PMID: 2297567
2. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004;104:1550-1558. PMID: 15150081
3. Wagner K, Damm F, Thol F, Gohring G, Gorlich K, Heuser M, et al. FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica. 2011;96:681-686. doi: 10.3324/haematol.2010.034074 PMID: 21242187
4. Yoon JH, Kim HJ, Shin SH, Lee SE, Cho BS, Eom KS, et al. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation? Biol Blood Marrow Transplant. 2014;20:80-88. doi: 10.1016/j.bbmt.2013.10.015 PMID: 24149098
5. Kroger N, Bacher U, Bader P, Bottcher S, Borowitz MJ, Dreger P, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010;16:1187-1211. doi: 10.1016/j.bbmt.2010. 06.008 PMID: 20558311
6. Kroger N, Bacher U, Bader P, Bottcher S, Borowitz MJ, Dreger P, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010;16:1325-1346. doi: 10.1016/j.bbmt. 2010.07.001 PMID: 20637879
7. Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2003;9:320-329. PMID: 12766882
8. Bethge WA, Hegenbart U, Stuart MJ, Storer BE, Maris MB, Flowers ME, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood. 2004;103:790-795. PMID: 14525766
9. Bretagne S, Vidaud M, Kuentz M, Cordonnier C, Henni T, Vinci G, et al. Mixed blood chimerism in T cell-depleted bone marrow transplant recipients: evaluation using DNA polymorphisms. Blood. 1987;70:1692-1695. PMID: 3311209
10. Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol. 2005;17:202-210. PMID: 15766682
11. De Bueger M, Bakker A, Van Rood J, Van Der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicated heterogenity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol. 1992;149:1788-1794. PMID: 1380540
12. Dickinson A, Wang X, Sviland L, Vyth-Dreese F, Jackson G, Schumacher T et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med. 2002;8:410-414. PMID: 11927949
13. Spierings E, Gras S, Reiser JB, Mommaas B, Almekinders M, Kester MG, et al. Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1Arg Null allele. J Immunol. 2009;182:4809-4816. doi: 10.4049/jimmunol.0803911 PMID: 19342659
14. Marijt W, Veenhof W, Goulmy E, Willemze R, Van Rood J, Falkenburg J. Minor histocompatibility antigens HA-1, -2, and -4, and HY-specific cytotoxic T-cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell-cell contact. Blood. 1993;82:3778-3785. PMID: 8260714
15. Van Der Harst D, Goulmy E, Falkenburg J, Kooij-Winkelaar Y, Van Luxemburg-Heijs S, Goselink H, et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood. 1994;83:1060-1066. PMID: 8111046
16. Falkenburg J, Goselink H, Van Der Harst D, Van Luxemburg-Heijs S, Kooy-Winkelaar Y, Faber L, et al. Growth inhibition of clonogeneic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med. 1991;174:27-33. PMID: 2056279
17. Wilke M, Dolstra H, Maas F, Pool J, Brouwer R, Falkenburg J, et al. Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematological malignancies. Hematol J. 2003;4:315-320. PMID: 14502255
18. Holloway PA, Kaldenhoven N, Van Dijk M, Bloem AC, De Lau W, Van Der ZR, et al. Susceptibility of malignant plasma cells to HA-1 (H) specific lysis suggests a role for the minor histocompatibility antigen HA-1 in the graft-versus-myeloma effect. Leukemia. 2004;18:1543-1545. PMID: 15322561
19. Hambach L, Nijmeijer B, Aghai Z, Schie M, Wauben M, Falkenburg J, et al. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia. 2006;20:371-374. PMID: 16357839
20. Marijt W, Heemskerk M, Kloosterboer F, Goulmy E, Kester M, Van Der Horn M, et al. Hematopoiesis-restricted minor histocompatibilty antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA. 2003;100:2742-2747. PMID: 12601144
21. Mutis T, Brand R, Gallardo D, Van Biezen A, Niederwieser D, Goulmy E. Graft-versus-host driven graftversusleukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients. Leukemia. 2010;24:1388-1392. doi: 10.1038/leu.2010.115 PMID: 20508613
22. Spierings E, Kim YH, Hendriks M, Borst E, Sergeant R, Canossi A, et al. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLAmatched related and unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:1244-1253. doi: 10.1016/j.bbmt.2013.06.001 PMID: 23756210
23. Hobo W, Broen K, Van Der Velden WJ, Greupink-Draaisma A, Adisty N, Wouters Y, et al. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:274-282. doi: 10.1016/j.bbmt.2012.09.008 PMID: 23022467
24. Spierings E, Drabbels J, Hendriks M, Pool J, Spruyt-Gerritse M, Claas F, et al. A uniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications. PLoS ONE. 2006;1:e42. PMID: 17183671
25. Mutis T, Gillespie G, Schrama E, Falkenburg J, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med. 1999;5:839-842. PMID: 10395333
26. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93:2336-2341. PMID: 10090944
27. Van Halteren AG, Jankowska-Gan E, Joosten A, Blokland E, Pool J, Brand A, et al. Naturally acquired tolerance and sensitization to minor histocompatibility antigens in healthy family members. Blood. 2009. 114:2263-72. doi: 10.1182/blood-2009-01-200410 PMID: 19506299
28. Goulmy E, Gratama JW, Blokland E, Zwaan FE, Van Rood JJ. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature. 1983;302:159-161. PMID: 6186923
29. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018. PMID: 8704209
30. Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R, et al. Clinical manifestations of graft-versushost disease in human recepients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304. PMID: 4153799
31. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versushost syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217. PMID: 6996481
32. Toes RE, Van Der Voort EI, Schoenberger SP, Drijfhout JW, Van Bloois L, Storm G, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol. 1998;160:4449-4456. PMID: 9574550
33. Bijker MS, Van Den Eeden SJ, Franken KL, Melief CJ, Van Der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol. 2008;38:1033-1042. doi: 10.1002/eji.200737995 PMID: 18350546
34. Stern M, Ruggeri L, Mancusi A, Bernardo ME, De Angelis C, Bucher C, et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood. 2008;112:2990-2995. doi: 10.1182/blood-2008-01-135285 PMID: 18492955
35. Verdijk R, Pool J, Van Der Keur M, Naipal A, Van Halteren A, Brand A, et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood. 2004;103:1961-1963. PMID: 14592836
36. Dierselhuis MP, Jankowska-Gan E, Blokland E, Pool J, Burlingham WJ, Van Halteren AG, et al. HY immune tolerance is common in women without male offspring. PLoS ONE. 2014;9(3):e91274. doi: 10. 1371/journal.pone.0091274 PMID: 24646895
37. Spierings E, Vermeulen C, Vogt M, Doerner L, Falkenburg J, Mutis T, et al. Identification of HLA class II-restricted H-Y specific T helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. Lancet. 2003;362:590-591. PMID: 12944055
38. Vogt M, Van Den Muijsenberg J, Goulmy E, Spierings E, Kluck P, Kester M, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versushost disease. Blood. 2002;99:3027-3032. PMID: 11929796
39. Boeck S, Hamann M, Pihusch V, Heller T, Diem H, Rolf B, et al. Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients. Bone Marrow Transplant. 2006;37:57-64. PMID: 16258592
40. Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia. 2014;28:1784-1792. doi: 10.1038/leu.2014.108 PMID: 24691076
41. Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121:1612-1621. doi: 10.1182/blood-2012-09-457531 PMID: 23247726
42. Borchers S, Bremm M, Lehrnbecher T, Dammann E, Pabst B, Wolk B, et al. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. PLoS ONE. 2012;7(12):e50248. doi: 10.1371/journal.pone.0050248 PMID: 23272059
43. Spierings E, Hendriks M, Absi L, Canossi A, Chhaya S, Crowley J, et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet. 2007;3(6):e103. PMID: 17604453
44. Wiedemann B, Klyuchnikov E, Kroger N, Zabelina T, Stahl T, Zeschke S, et al. Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia. Exp Hematol. 2010;38:1261-1271. doi: 10.1016/j.exphem.2010.08.006 PMID: 20851159
45. Rufer N, Starobinski M, Chapuis B, Gratwohl A, Jeannet M, Helg C, et al. Clinical consequences of sensitisation to minor histocompatibility antigens before allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998;22:895-898. PMID: 9827818
46. Bonnet D, Warren E, Greenberg P, Dick J, Riddell S. CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA. 2001;96:8639-8644.
47. Rosinski KV, Fujii N, Mito JK, Koo KK, Xuereb SM, Sala-Torra O, et al. DDX3Y encodes a class I MHCrestricted H-Y antigen that is expressed in leukemic stem cells. Blood. 2008;111:4817-4826. doi: 10. 1182/blood-2007-06-096313 PMID: 18299450
48. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737. PMID: 9212098
49. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68:190-197. doi: 10.1158/0008-5472. CAN-07-3096 PMID: 18172311
50. Martinez-Climent JA, Fontan L, Gascoyne RD, Siebert R, Prosper F. Lymphoma stem cells: enough evidence to support their existence? Haematologica. 2010;95:293-302. doi: 10.3324/haematol.2009. 013318 PMID: 20139392